Unknown

Dataset Information

Aspirin Does Not Increase Heart Failure Events in Heart Failure Patients: From the WARCEF Trial.


ABSTRACT:

Objectives

The aim of this study was to determine whether aspirin increases heart failure (HF) hospitalization or death in patients with HF with reduced ejection fraction receiving an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB).

Background

Because of its cyclooxygenase inhibiting properties, aspirin has been postulated to increase HF events in patients treated with ACE inhibitors or ARBs. However, no large randomized trial has addressed the clinical relevance of this issue.

Methods

We compared aspirin and warfarin for HF events (hospitalization, death, or both) in the 2,305 patients enrolled in the WARCEF (Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction) trial (98.6% on ACE inhibitor or ARB treatment), using convent

SUBMITTER: Teerlink JR 

PROVIDER: S-EPMC5570544 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature